###### 

Characteristics for LM-initiated patients

                                                                   All LM Events (n=74)   Group 1: Baseline CD4 200 cell/µL (n=64)   Group 2: Baseline CD4=200 cells/µL (n=10)   p
  ---------------------------------------------------------------- ---------------------- ------------------------------------------ ------------------------------------------- --------
  Male (n, %)                                                      43 (58)                38 (59)                                    5 (50)                                      0.576
  Age at LM initiation, years (median, IQR)                        9.7 (6.5--11.8)        9.0 (6.4--11.2)                            11.9 (10--14.4)                             0.010
  Duration of LM, months (median, IQR)                             11.5 (7.1--17.4)       12.9 (7.4--17.9)                           7.1 (5.1--9.1)                              0.126
  Final CD4, cells/µL (IQR, final prior to switch or last on LM)   429 (212--593)         471 (325--632)                             29 (16--59)                                 0.0001
  Patients with overall decrease in CD4 (n, %)                     64 (86.5)              58 (90.6)                                  6 (60)                                      0.185
  Patients with 25% decrease in CD4 (n, %)                         50 (67.6)              44 (68.8)                                  6 (60)                                      0.325
  Patients switched to second or third line therapy (n, %)         17 (23)                11 (17.2)                                  6 (60)                                      0.003
  Stage 3 or 4 event (n, %)                                        6 (8.1)                5 (7.8)                                    1 (10)                                      0.814
